N/A N=17 Randomized Study of Daytime vs. Delayed Eating: Effect on Weight and Metabolism
Obesity
Primary: Body Mass Changes Between the Daytime vs. Delayed Eating Conditions — -1.1; 0.2 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
N/A N=53 A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
Pulmonary Fibrosis
Primary: Cough Count Per Hour (CC/hr) Measured Over a 24-hour Period at Baseline Visit, Week 4, Week 8, and at Day 82 — 10.79; 12.63; 10.36; 12.45 Cough count per hour
N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
N/A N=1,934 Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool
COVID-19 Vaccines · Telemedicine · Vaccine Hesitancy
Primary: Proportion of Children Who Complete COVID-19 Vaccination, as Verified in State, Clinic, or Participant-held Records — 13; 7 Participants
Phase 2 N=267 A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Malignant Rhabdoid Tumors (MRT) · Rhabdoid Tumors of the Kidney (RTK) · Atypical Teratoid Rhabdoid Tumors (ATRT)
Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants
Phase 4 N=147 Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
Obesity
Primary: Phase 1: Percent Weight Loss — 1.7; 0.9; 0.3 % change in weight
N/A N=85 Food Pantry Client and Staff Preferences for Nutritious no Prep Ready-to-eat Meals
Diet, Healthy · Food Security
Primary: Hedonic Liking of Study Foods — 7.2; 7.2 score on a scale
N/A N=5 Using an Interactive Virtual Reality System to Distract Burns Patients During Burn Treatments
Burns
Primary: Pain Scores — 44.0; 52.50 score on a scale
N/A N=182 Telerehabilitation in People With Long COVID
COVID-19
Primary: Change in Exercise Capacity: Peak Oxygen Uptake (VO2peak) From Baseline to 12 Weeks — 2.4; 1.7 ml/kg/min
N/A N=370 GEnetic Counseling Through Virtual Visits in Parkinson's Disease
Parkinson Disease
Primary: Genetics Knowledge — 16; 17; 17; 16 score on a scale
N/A N=8,158 Triaging and Referring in Adjacent General and Emergency Departments
Triage
Primary: The Proportion of Patients Presenting at the ED But Being Treated by the GPC After Referral — 599; 0 Participants
N/A N=26 The Breakfast Rise, Education and Knowledge Study
type1diabetes
Primary: Mean Glucose (mmol/l) — 9.5; 8.0; 8.7; 8.4 mmol/l — p=0.12
Phase 2 N=64 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma
Primary: Overall Response Rate (ORR) as Assessed by Central Imaging Facility Based on RECIST v1.1 — 38.7 percentage of participants — p=0.0002
Phase 2 N=327 Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Non-segmental Vitiligo
Primary: Mean Change From Baseline in Vitiligo Area Scoring Index Score — -0.472; -0.271; -0.706; -1.145 score on a scale — p=0.7905